

Date: Friday, 08th October 2021
Our Ref: MB/SS FOI 4894

Sid Watkins Building
Lower Lane
Fazakerley
Liverpool L9 7BB
Tel: 01515253611
Fax: 01515295500
Direct Line: 01515563038

Re: Freedom of Information Request FOI 4894

We are writing in response to your request submitted under the Freedom of Information Act, received in this office on 15th September 2021.

Your request was as follows:

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaferon (interferon beta-1b)
- Brabio (glatiramer acetate)
- Copaxone (glatiramer acetate)
- Extavia (beta interferon-1b)
- Fampyra (fampridine)
- Gilenya (fingolimod)
- Lemtrada (alemtuzumab)
- Mavenclad (cladribine)
- Mayzent (siponimod)

- Ocrevus (ocrelizumab)
- Plegridy (peginterferon beta-1a)
- Rebif (beta interferon-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
- Zeposia (ozanimod)

ALEMTUZUMAB 12 mg in 1.2ml injection □3

CLADRIBINE (HOMECARE) 10 mg tablets □4

DIMETHYL FUMARATE (TECFIDERA HOMECARE) 120 mg capsules □21

DIMETHYL FUMARATE (TECFIDERA HOMECARE) 240 mg capsules □275

FAMPRIDINE (HOMECARE) 10 mg MR tablets □1

FINGOLIMOD (HOMECARE) Packsize 28 (Maintenance) 500 micrograms capsules □143

FINGOLIMOD 500 micrograms capsules □6

GLATIRAMER (HOMECARE) 20 mg in 1ml injection □55

GLATIRAMER (HOMECARE) 40 mg in 1ml injection □298

INTERFERON BETA 1a HOMECARE (AVONEX) 30 micrograms in 0.5ml injection □9

INTERFERON BETA 1a HOMECARE (AVONEX) PEN 30 micrograms in 0.5ml injection □9

INTERFERON BETA 1a HOMECARE (REBIJECT) 22 micrograms in 0.5ml injection □24

INTERFERON BETA 1a HOMECARE (REBIJECT) 44 micrograms in 0.5ml injection □11

INTERFERON BETA 1a HOMECARE (REBISMART) 22 micrograms in 0.5ml injection □18

INTERFERON BETA 1a HOMECARE (REBISMART) 44 micrograms in 0.5ml injection □23

INTERFERON Beta 1b HOMECARE (BETAFERON) DELIVERY CHARGE Pack □1

INTERFERON Beta 1b HOMECARE (BETAFERON) 250 micrograms in 1ml injection □3

NATALIZUMAB (VIAL) 300 mg infusion □102

OCRELIZUMAB 300 mg in 10ml injection □87

PEGINTERFERON INITIATION PACK (HOMECARE) injection □6

PEGINTERFERON beta 1A (HOMECARE) 125 micrograms in 0.5ml injection □34

PEGVISOMANT (HOMECARE) 30 mg injection □1

TERIFLUNOMIDE (HOMECARE) 14 mg tablets □57

Q2. How many patients have been treated with the following drugs in the past 4 months:

- Aimovig (ereenumab) - any disease

- Ajoovy (fremanezumab) - any disease
- Emgality (galcanezumab) - any disease
- Botulinum Toxin (i.e. Botox, Dysport, Xeomin) - for migraine ONLY

ERENUMAB (HOMECARE) 140 mg injection 13

ERENUMAB FOC (HOMECARE) 70 mg injection 2

FREMANEZUMAB (HOMECARE) PEN 225 mg in 1.5ml injection 337

GALCANEZUMAB (HOMECARE) 120 mg injection 13

Q3. Does the trust either commission or fund Botulinum Toxin treatment and/or anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality) for migraine (Y/N)?

Yes

Q4. How many patients have been treated in the past 4 months for the following conditions:

- Chronic migraine (15+ headache days per month)
- Episodic migraine (4-14 headache days per month)
- Relapsing remitting multiple sclerosis (RRMS)
- Primary progressive multiple sclerosis (PPMS)
- Secondary progressive multiple sclerosis (SPMS)

Please note we don't hold the number of days a patient is suffering migraines in a month. Please see the total number of chronic migraines listed below.

Relapsing remitting MS (RRMS) - 633

Secondary progressive MS (SPMS) - 133

Primary progressive MS (PPMS) - 64

Multiple Sclerosis - any type - 1932

Chronic Migraine - 674

Please see our response above in [blue](#).

Re-Use of Public Sector Information

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of

Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information can be found at www.opsi.gov.uk where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at www.opsi.gov.uk/advice/psi-regulations/index.htm

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to the Freedom of Information Office at the address above.

Please remember to quote the reference number, FOI 4894 in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Yours sincerely

Mike Burns

Mr. Mike Burns, Executive Lead for Freedom of Information